IRIX Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -12.6% compared to IRIDEX Corp.'s net margin of 14.61%. IRIDEX Corp.'s return on equity of -155.93% beat Electromed, Inc.'s return on equity of 20.35%.

IRIDEX Corp. has a consensus price target of $3.00, signalling upside risk potential of 105.48%. On the other hand Electromed, Inc. has an analysts' consensus of $37.00 which suggests that it could grow by 53.72%. Given that IRIDEX Corp. has higher upside potential than Electromed, Inc., analysts believe IRIDEX Corp. is more attractive than Electromed, Inc..

IRIDEX Corp. has a beta of 0.705, which suggesting that the stock is 29.514% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.264, suggesting its less volatile than the S&P 500 by 73.581%.

IRIDEX Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX Corp. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

IRIDEX Corp. quarterly revenues are $12.5M, which are smaller than Electromed, Inc. quarterly revenues of $18.9M. IRIDEX Corp.'s net income of -$1.6M is lower than Electromed, Inc.'s net income of $2.8M. Notably, IRIDEX Corp.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 23.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX Corp. is 0.48x versus 3.06x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Escalon Medical Corp. has a net margin of -12.6% compared to IRIDEX Corp.'s net margin of 2.72%. IRIDEX Corp.'s return on equity of -155.93% beat Escalon Medical Corp.'s return on equity of -12.94%.

IRIDEX Corp. has a consensus price target of $3.00, signalling upside risk potential of 105.48%. On the other hand Escalon Medical Corp. has an analysts' consensus of -- which suggests that it could grow by 4900%. Given that Escalon Medical Corp. has higher upside potential than IRIDEX Corp., analysts believe Escalon Medical Corp. is more attractive than IRIDEX Corp..

IRIDEX Corp. has a beta of 0.705, which suggesting that the stock is 29.514% less volatile than S&P 500. In comparison Escalon Medical Corp. has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.1%.

IRIDEX Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Escalon Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX Corp. pays -- of its earnings as a dividend. Escalon Medical Corp. pays out -- of its earnings as a dividend.

IRIDEX Corp. quarterly revenues are $12.5M, which are larger than Escalon Medical Corp. quarterly revenues of $3.6M. IRIDEX Corp.'s net income of -$1.6M is lower than Escalon Medical Corp.'s net income of $97.7K. Notably, IRIDEX Corp.'s price-to-earnings ratio is -- while Escalon Medical Corp.'s PE ratio is 154.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX Corp. is 0.48x versus 0.21x for Escalon Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Guided Therapeutics, Inc. has a net margin of -12.6% compared to IRIDEX Corp.'s net margin of -1236.67%. IRIDEX Corp.'s return on equity of -155.93% beat Guided Therapeutics, Inc.'s return on equity of --.

IRIDEX Corp. has a consensus price target of $3.00, signalling upside risk potential of 105.48%. On the other hand Guided Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 30270170.27%. Given that Guided Therapeutics, Inc. has higher upside potential than IRIDEX Corp., analysts believe Guided Therapeutics, Inc. is more attractive than IRIDEX Corp..

IRIDEX Corp. has a beta of 0.705, which suggesting that the stock is 29.514% less volatile than S&P 500. In comparison Guided Therapeutics, Inc. has a beta of 0.606, suggesting its less volatile than the S&P 500 by 39.441%.

IRIDEX Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guided Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IRIDEX Corp. pays -- of its earnings as a dividend. Guided Therapeutics, Inc. pays out -- of its earnings as a dividend.

IRIDEX Corp. quarterly revenues are $12.5M, which are larger than Guided Therapeutics, Inc. quarterly revenues of $60K. IRIDEX Corp.'s net income of -$1.6M is lower than Guided Therapeutics, Inc.'s net income of -$742K. Notably, IRIDEX Corp.'s price-to-earnings ratio is -- while Guided Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IRIDEX Corp. is 0.48x versus 150.88x for Guided Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.